# A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection

> **NCT04198363** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 510 (actual)

## Conditions studied

- Helicobacter Pylori

## Interventions

- **DRUG:** Vonoprazan
- **DRUG:** Amoxicillin
- **DRUG:** Clarithromycin
- **DRUG:** Bismuth Potassium citrate
- **DRUG:** Esomeprazole

## Key facts

- **NCT ID:** NCT04198363
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-30
- **Primary completion:** 2021-11-01
- **Final completion:** 2021-11-25
- **Target enrollment:** 510 (ACTUAL)
- **Last updated:** 2023-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04198363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04198363, "A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04198363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*